電気泳動の市場規模、シェア、動向分析レポート：製品別、用途別、最終用途別、地域別、セグメント別予測、2025～2030年

電気泳動の市場規模と動向

世界の電気泳動市場規模は2024年に32億9,000万米ドルと推定され、2025～2030年にかけてCAGR 5.62％で成長すると予測されています。

市場成長の背景には、先進的診断ツールに対する需要の高まり、バイオテクノロジーや医療研究に対する投資の増加、効率的なタンパク質・核酸分析に対するニーズの高まりがあります。電気泳動は、医薬品開発、疾病診断、研究など様々な用途で重要な役割を担っており、より洗練された高性能システムの需要を牽引しています。バイオテクノロジー、製薬、学術の各セグメントが精密医療や遺伝子研究に力を入れ続ける中、タンパク質、DNA、RNAを分離・分析するための信頼性が高く効率的な電気泳動システムのニーズが高まっています。

成長の主要原動力のひとつは、技術の絶え間ない進歩です。実験の効率と再現性を高める自動化システムの開発により、世界中のラボでこれらの技術の採用が増加しています。さらに、高分解能電気泳動や多重化機能の統合などの技術革新により、これらのシステムの感度とスループットが向上しています。これらの進歩により、電気泳動は、臨床診断、学術研究、バイオ医薬品など、さまざまな産業の進化する要求に応えることができる、より身近で汎用性の高いものとなりつつあります。たとえば、Agilent ProteoAnalyzerシステムは、タンパク質分析用に設計された先進的自動パラレルキャピラリー電気泳動プラットフォームです。この革新的なソリューションは、複雑なタンパク質混合物の分析を合理化・最適化し、製薬、バイオテクノロジー、食品分析、学術研究など幅広い産業に貢献しています。

個別化医療と標的療法への注目の高まりも、市場の成長を促す重要な要因です。医療がより個別化された治療へとシフトするにつれ、遺伝子検査、バイオマーカー同定、分子診断が医療研究や臨床診療に不可欠な要素となっています。電気泳動はこれらのセグメントで不可欠な役割を果たしており、病気の検出、治療法の選択、治療効果のモニタリングに使用できる生体分子の精密な分離と分析を可能にしています。遺伝子検査に対する需要の高まりや、腫瘍学、神経学、その他の治療セグメントにおける電気泳動の利用拡大が、市場の成長をさらに促進すると予想されます。

さらに、電気泳動産業を牽引するもう一つの重要な要因は、臨床検査室や診断センターからの需要の増加です。特に遺伝子検査、血液分析、タンパク質プロファイリングのセグメントで、ルーチン検査や疾病診断に電気泳動技術を採用する臨床検査機関が増えるにつれて、市場は着実に拡大しています。さらに、早期発見のために精密な分子診断技術を必要とするがん、糖尿病、心血管疾患などの慢性疾患の罹患率が上昇していることも、電気泳動ベースのシステムに対する需要を高めています。

さらに、製薬会社やバイオテクノロジー企業も、新薬や治療法を発見するための研究開発（R&D）に多額の投資を行い、市場開拓に貢献しています。電気泳動は、潜在的な薬剤候補のスクリーニングからタンパク質相互作用の分析、治療用抗体の特性評価まで、医薬品開発プロセスで広く利用されています。製薬企業が革新的な生物製剤の創製に注力し続ける中、高性能分析や詳細なタンパク質プロファイリングが可能な先進的システムへの需要が高まっています。この成長は、モノクローナル抗体開発や遺伝子治療など、電気泳動が複雑な分子の分析に不可欠なセグメントで特に顕著です。

しかし、先進的システムとそのメンテナンスに伴う高コストが、市場成長の大きな抑制要因となっています。これらのシステム、特に高スループットまたは自動化プラットフォームは、操作のために多額の設備投資、特殊な機器、熟練した人材を必要とすることが多く、予算が限られている小規模ラボや新興市場のラボにとっては利用しにくいものとなっています。さらに、特定の電気泳動技術は複雑であるため、適切に管理されなければ、トレーニング期間が長くなり、エラーが発生する可能性があります。これらのシステムは優れた精度と効率を提供する一方で、そのコストと操作上の要求から、特に低資源環境では導入が制限される可能性があります。さらに、地域によっては技術導入のペースが遅く、規制上の障壁や規制当局の承認の必要性と相まって、特定の地域における市場成長の妨げとなる可能性があります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 電気泳動市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 電気泳動市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析

第4章 電気泳動市場：製品別、推定・動向分析

• 世界の電気泳動市場：製品ダッシュボード
• 世界の電気泳動市場：製品変動分析
• 世界の電気泳動市場：製品別、収益別
• 電気泳動試薬
  • タンパク質電気泳動試薬
  • 核酸電気泳動試薬
• 電気泳動システム
  • ゲル電気泳動システム
  • キャピラリー電気泳動システム
• ゲルドキュメンテーションシステム
• ソフトウェア

第5章 電気泳動市場：用途別、推定・動向分析

• 世界の電気泳動市場：用途ダッシュボード
• 世界の電気泳動市場：用途変動分析
• 世界の電気泳動市場：用途別、収益別
• 研究用途
• 診断用途
• 品質管理とプロセス検証

第6章 電気泳動市場：最終用途別、推定・動向分析

• 世界の電気泳動市場：最終用途ダッシュボード
• 世界の電気泳動市場：最終用途変動分析
• 世界の電気泳動市場：最終用途別、収益別
• 学術研究機関
• 製薬・バイオテクノロジー企業
• 病院と診断センター
• その他

第7章 電気泳動市場：製品、用途、最終用途による地域別、推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店とチャネルパートナー一覧
  • 主要企業の市場シェア分析、2024年
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Merck KGaA
  • GE Healthcare
  • QIAGEN
  • Lonza Group Ltd.
  • PerkinElmer, Inc.
  • Danaher
  • Harvard Bioscience, Inc.
  • Shimadzu Corporation

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Million)
• Table 4 Global Oncology Companion Diagnostic, by Application, 2018 - 2030 (USD Million)
• Table 5 Global Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 6 Global Oncology Companion Diagnostic, by Region, 2018 - 2030 (USD Million)
• Table 7 North America Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
• Table 8 North America Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Million)
• Table 9 North America Oncology Companion Diagnostic, by Application, 2018 - 2030 (USD Million)
• Table 10 North America Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 11 U.S. Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Million)
• Table 12 U.S. Oncology Companion Diagnostic, by Application, 2018 - 2030 (USD Million)
• Table 13 U.S. Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 14 Canada Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Million)
• Table 15 Canada Oncology Companion Diagnostic, by Application, 2018 - 2030 (USD Million)
• Table 16 Canada Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 17 Mexico Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Million)
• Table 18 Mexico Oncology Companion Diagnostic, by Application, 2018 - 2030 (USD Million)
• Table 19 Mexico Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 20 Europe Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
• Table 21 Europe Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Million)
• Table 22 Europe Oncology Companion Diagnostic, by Application, 2018 - 2030 (USD Million)
• Table 23 Europe Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 24 Germany Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Million)
• Table 25 Germany Oncology Companion Diagnostic, by Application, 2018 - 2030 (USD Million)
• Table 26 Germany Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 27 UK Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Million)
• Table 28 UK Oncology Companion Diagnostic, by Application, 2018 - 2030 (USD Million)
• Table 29 UK Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 30 France Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Million)
• Table 31 France Oncology Companion Diagnostic, by Application, 2018 - 2030 (USD Million)
• Table 32 France Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 33 Italy Oncology Companion Diagnostic, by Product, 2018 - 2030 (USD Million)
• Table 34 Italy Oncology Companion Diagnostic, by Application, 2018 - 2030 (USD Million)
• Table 35 Italy Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
• Table 36 Spain Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 37 Spain Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 38 Spain Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 39 Denmark Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 40 Denmark Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 41 Denmark Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 42 Sweden Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 43 Sweden Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 44 Sweden Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 45 Norway Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 46 Norway Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 47 Norway Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 48 Asia Pacific Electrophoresis, by Country, 2018 - 2030 (USD Million)
• Table 49 Asia Pacific Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 50 Asia Pacific Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 51 Asia Pacific Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 52 China Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 53 China Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 54 China Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 55 Japan Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 56 Japan Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 57 Japan Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 58 India Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 59 India Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 60 India Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 61 South Korea Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 62 South Korea Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 63 South Korea Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 64 Australia Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 65 Australia Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 66 Australia Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 67 Thailand Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 68 Thailand Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 69 Thailand Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 70 Latin America Electrophoresis, by Country, 2018 - 2030 (USD Million)
• Table 71 Latin America Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 72 Latin America Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 73 Latin America Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 74 Brazil Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 75 Brazil Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 76 Brazil Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 77 Argentina Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 78 Argentina Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 79 Argentina Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa Electrophoresis, by Country, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 83 Middle East & Africa Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 84 South Africa Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 85 South Africa Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 86 South Africa Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 89 Saudi Arabia Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 90 UAE Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 91 UAE Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 92 UAE Electrophoresis, by End Use, 2018 - 2030 (USD Million)
• Table 93 Kuwait Electrophoresis, by Product, 2018 - 2030 (USD Million)
• Table 94 Kuwait Electrophoresis, by Application, 2018 - 2030 (USD Million)
• Table 95 Kuwait Electrophoresis, by End Use, 2018 - 2030 (USD Million)

List of Figures

• FIG. 1 Market research process
• FIG. 2 Information Procurement
• FIG. 3 Primary Research Pattern
• FIG. 4 Market Research Approaches
• FIG. 5 Value Chain-Based Sizing & Forecasting
• FIG. 6 Market Formulation & Validation
• FIG. 7 Electrophoresis Market Segmentation
• FIG. 8 Market Snapshot, 2023
• FIG. 9 Market Trends & Outlook
• FIG. 10 Market Driver Relevance Analysis (Current & Future Impact)
• FIG. 11 Market Restraint Relevance Analysis (Current & Future Impact)
• FIG. 12 Market Challenge Relevance Analysis (Current & Future Impact)
• FIG. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• FIG. 14 Porter's Five Forces Analysis
• FIG. 15 Global Electrophoresis Market: Product Movement Analysis
• FIG. 16 Global Electrophoresis Market, for Electrophoresis Reagents, 2018 - 2030 (USD Million)
• FIG. 17 Global Electrophoresis Market, for Electrophoresis Systems, 2018 - 2030 (USD Million)
• FIG. 18 Global Electrophoresis Market, for Gel Documentation Systems, 2018 - 2030 (USD Million)
• FIG. 19 Global Electrophoresis Market, for Software, 2018 - 2030 (USD Million)
• FIG. 20 Global Electrophoresis Market: Application Movement Analysis
• FIG. 21 Global Electrophoresis Market, for Research Applications, 2018 - 2030 (USD Million)
• FIG. 22 Global Electrophoresis Market, for Diagnostics Applications, 2018 - 2030 (USD Million)
• FIG. 23 Global Electrophoresis Market, for Quality Control and Process Validation, 2018 - 2030 (USD Million)
• FIG. 24 Global Electrophoresis Market: End Use Movement Analysis
• FIG. 25 Global Electrophoresis Market, for Academic and Research Institutes, 2018 - 2030 (USD Million)
• FIG. 26 Global Electrophoresis Market, for Pharmaceutical and Biotechnology Companies, 2018 - 2030 (USD Million)
• FIG. 27 Global Electrophoresis Market, for Hospital and Diagnostic Centers, 2018 - 2030 (USD Million)
• FIG. 28 Global Electrophoresis Market, for Other End Use, 2018 - 2030 (USD Million)
• FIG. 29 Regional Marketplace: Key Takeaways
• FIG. 30 Regional Outlook, 2023 & 2030
• FIG. 31 Global Electrophoresis Market: Region Movement Analysis
• FIG. 32 North America Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 33 U.S. Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 34 Canada Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 35 Mexico Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 36 Europe Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 37 Germany Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 38 UK Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 39 France Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 40 Italy Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 41 Spain Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 42 Denmark Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 43 Sweden Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 44 Norway Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 45 Asia Pacific Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 46 Japan Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 47 China Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 48 India Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 49 Australia Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 50 South Korea Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 51 Thailand Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 52 Latin America Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 53 Brazil Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 54 Argentina Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 55 Middle East and Africa Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 56 South Africa Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 57 Saudi Arabia Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 58 UAE Electrophoresis Market, 2018 - 2030 (USD Million)
• FIG. 59 Kuwait Electrophoresis Market, 2018 - 2030 (USD Million)

Electrophoresis Market Size & Trends:

The global electrophoresis market size was estimated at USD 3.29 billion in 2024 and is projected to grow at a CAGR of 5.62% from 2025 to 2030. The growth of the market is attributed to the increasing demand for advanced diagnostic tools, rising investments in biotechnology and healthcare research, and the growing need for efficient protein and nucleic acid analysis. Electrophoresis plays a critical role in various applications such as drug development, disease diagnosis, and research, driving the demand for more sophisticated, high-throughput systems. As the biotechnology, pharmaceutical, and academic sectors continue to focus on precision medicine and genetic research, the need for reliable and efficient electrophoresis systems to separate and analyze proteins, DNA, and RNA is on the rise.

One of the major drivers of growth is the continuous advancements in technology. The development of automated systems, which enhance the efficiency and reproducibility of experiments, is increasing the adoption of these techniques across laboratories worldwide. Additionally, innovations such as high-resolution electrophoresis and the integration of multiplexing capabilities are improving the sensitivity and throughput of these systems. With these advancements, electrophoresis is becoming more accessible and versatile, capable of meeting the evolving demands of various industries, including clinical diagnostics, academic research, and biopharmaceuticals. For instance, the Agilent ProteoAnalyzer system, which is an advanced automated parallel capillary electrophoresis platform designed for protein analysis. This innovative solution streamlines and optimizes the analysis of complex protein mixtures, serving a wide range of industries including pharmaceuticals, biotechnology, food analysis, and academic research.

The rising emphasis on personalized medicine and targeted therapies is another significant factor driving the growth of the market. As healthcare shifts towards more tailored treatments, genetic testing, biomarker identification, and molecular diagnostics have become essential components of medical research and clinical practice. Electrophoresis plays an integral role in these areas, enabling the precise separation and analysis of biomolecules that can be used for disease detection, treatment selection, and monitoring therapeutic efficacy. The increasing demand for genetic testing and the expanding use of electrophoresis in oncology, neurology, and other therapeutic areas are expected to further fuel market growth.

Furthermore, another key factor driving the electrophoresis industry is the increasing demand from clinical laboratories and diagnostic centers. As more clinical laboratories adopt electrophoresis techniques for routine testing and disease diagnosis, particularly in the areas of genetic testing, blood analysis, and protein profiling, the market is experiencing a steady uptick in adoption. Additionally, the rising incidence of chronic diseases such as cancer, diabetes, and cardiovascular diseases, which require precise molecular diagnostic techniques for early detection, further contributes to the demand for electrophoresis-based systems.

Moreover, Pharmaceutical and biotechnology companies are also contributing to the market expansion by investing heavily in research and development (R&D) to discover new drugs and therapies. Electrophoresis is widely used in the drug development process, from screening potential drug candidates to analyzing protein interactions and characterizing therapeutic antibodies. As pharmaceutical companies continue to focus on creating innovative biologic drugs, the demand for advanced systems capable of high-throughput analysis and detailed protein profiling is rising. This growth is particularly evident in areas such as monoclonal antibody development and gene therapy, where electrophoresis is crucial for analyzing complex molecules.

However, the high cost associated with advanced systems and their maintenance is a major restraining factor for growth of the market. These systems, particularly high-throughput or automated platforms, often require significant capital investment, specialized equipment, and skilled personnel for operation, making them less accessible to smaller laboratories or those in emerging markets with limited budgets. Additionally, the complexity of certain electrophoresis techniques can result in longer training periods and potential errors if not properly managed. While these systems offer superior accuracy and efficiency, their cost and operational demands can limit adoption, particularly in low-resource settings. Furthermore, the slow pace of technology adoption in some regions, coupled with regulatory barriers and the need for regulatory approvals, can hinder market growth in certain areas.

Global Electrophoresis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global electrophoresis market report based on product, application, end Use, and region.

• Product Outlook (Revenue, USD Million; 2018 - 2030)
• Electrophoresis Reagents
  • Protein Electrophoresis Reagents
  • Nucleic Acid Electrophoresis Reagents
• Electrophoresis Systems
  • Gel Electrophoresis Systems
  • Capillary Electrophoresis Systems
• Gel Documentation Systems
• Software
• Application Outlook (Revenue, USD Million; 2018 - 2030)
• Research Applications
• Diagnostics Applications
• Quality Control and Process Validation
• End Use Outlook (Revenue, USD Million; 2018 - 2030)
• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Hospital and Diagnostic Centers
• Other End Use
• Regional Outlook (Revenue, USD Million; 2018 - 2030)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End Use outlook
• 2.3. Competitive Insights

Chapter 3. Electrophoresis Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of chronic diseases
    • 3.2.1.2. Increasing industry academia collaborations
    • 3.2.1.3. Rising need for personalized medicines
    • 3.2.1.4. Technological advancements
    • 3.2.1.5. Increasing funding for genomics and proteomics research
    • 3.2.1.6. Rising number of clinical laboratories
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Untrained personnel
    • 3.2.2.2. Stringent regulations
• 3.3. Electrophoresis Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Electrophoresis Market: Product Estimates & Trend Analysis

• 4.1. Global Electrophoresis Market: Product Dashboard
• 4.2. Global Electrophoresis Market: Product Movement Analysis
• 4.3. Global Electrophoresis Market by Product , Revenue
• 4.4. Electrophoresis Reagents
  • 4.4.1. Electrophoresis reagents market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Protein Electrophoresis Reagents
    • 4.4.2.1. Protein electrophoresis reagents market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Nucleic Acid Electrophoresis Reagents
    • 4.4.3.1. Nucleic acid electrophoresis reagents market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Electrophoresis Systems
  • 4.5.1. Electrophoresis systems market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Gel Electrophoresis Systems
    • 4.5.2.1. Electrophoresis systems market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Capillary Electrophoresis Systems
    • 4.5.3.1. Capillary electrophoresis systems market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Gel Documentation Systems
  • 4.6.1. Gel documentation systems market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Software
  • 4.7.1. Software market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Electrophoresis Market: Application Estimates & Trend Analysis

• 5.1. Global Electrophoresis Market: Application Dashboard
• 5.2. Global Electrophoresis Market: Application Movement Analysis
• 5.3. Global Electrophoresis Market by Application, Revenue
• 5.4. Research Applications
  • 5.4.1. Research applications market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Diagnostics Applications
  • 5.5.1. Diagnostics applications market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Quality Control and Process Validation
  • 5.6.1. Quality control and process validation market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Electrophoresis Market: End Use Estimates & Trend Analysis

• 6.1. Global Electrophoresis Market: Ens-use Dashboard
• 6.2. Global Electrophoresis Market: End Use Movement Analysis
• 6.3. Global Electrophoresis Market by End Use, Revenue
• 6.4. Academic and Research Institutes
  • 6.4.1. Academic and research institutes market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Pharmaceutical and Biotechnology Companies
  • 6.5.1. Pharmaceutical and biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Hospital and Diagnostic Centers
  • 6.6.1. Hospital and diagnostic centers market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Other End Use
  • 6.7.1. Other end use market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Electrophoresis Market: Regional Estimates & Trend Analysis by Product, Application, and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Bio-Rad Laboratories, Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Thermo Fisher Scientific Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Agilent Technologies, Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Merck KGaA
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. GE Healthcare
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. QIAGEN
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Lonza Group Ltd.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. PerkinElmer, Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Danaher
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Harvard Bioscience, Inc.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Shimadzu Corporation
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives